Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Risperdal OD vs Risperdal Quicklet
NCT02012049Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2009
- Primary completion
- Aug 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of risperidone in schizophrenia (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Plasma concentrations of Risperidone at 24 hours. Started Aug 2009; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02012049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02012049.